Company profile

Ticker
TENX
Exchange
CEO
Anthony A. DiTonno
Employees
Incorporated in
Location
Fiscal year end
Former names
Oxygen Biotherapeutics, Inc., Synthetic Blood International Inc
SEC CIK
IRS number
262593535

TENX stock data

(
)

Calendar

14 Aug 19
21 Aug 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue
Net income 1.76M 1.62M -18.73M 1.53M
Diluted EPS -0.28 -0.33 -5.87 -1.05
Operating income 1.82M 1.66M -11.56M 1.55M
Net change in cash -1.91M -2.05M 9.02M -555.7K
Cash on hand 8.41M 10.32M 12.37M 3.35M
Cost of revenue
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 0
Net income -14.14M -8.84M -43.92M
Diluted EPS -9.04 -6.27 -31.24
Operating income -6.89M -9.21M -52.65M
Net change in cash 2.87M -12.4M -16.3M
Cash on hand 12.37M 9.5M 21.9M 38.2M
Cost of revenue 0

Financial data from company earnings reports

Financial report summary

?
Competition
Cytokinetics
Management Discussion
  • Cash and cash equivalents, including the fair-value of our marketable securities, were $8.9 million at June 30, 2019.
  • Our net loss from operations was $1.8 million for the second quarter of fiscal 2019 compared to $1.9 million for the three months ended June 30, 2018.
  • Net cash used in operating activities was $1.9 million and $1.2 million for the three months ended June 30, 2019 and 2018, respectively.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: advisory, arbitration, attached, correct, declaration, deteriorate, disagreement, dispute, economic, entirety, Finnish, firm, inconsistent, interpretation, line, oral, outreach, proxy, reimburse, rejected, relationship, rely, request, requested, resolved, response, scientific, shareholder, solicitation, strain
Removed: connection